Skip to main content
SpringerLink
Log in

Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue

  • Original Article
  • Published:
Brain Tumor Pathology Aims and scope Submit manuscript

Abstract

Recent reports have suggested an important clinical role for hypermethylation of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter in patients with glioblastomas. Whether MGMT protein expression is correlated with promoter hypermethylation and patient outcomes, however, has not been elucidated. Here we describe a quantitative digital method for assessment of MGMT-specific immunostaining, and analyze the relationship between expression levels and methylation status of the MGMT promoter. We investigated 46 tumors from patients who received a diagnosis of glioblastoma or gliosarcoma. Immunohistochemistry with anti-MGMT antibody and methylation-specific PCR using bisulfite-modified tumor DNA were performed. The digital assessment method used image-analysis software to determine a digital MGMT staining index, and the results were compared with those obtained via conventional visual assessments. The digital staining index clearly correlated with the methylation status of MGMT promoter. In addition, the index correlated with our observational results when nuclear and cytoplasmic staining were assessed in three different fields. Our digital assessment method enabled us to assess uncertain immunopositive samples objectively and quantitatively, which is an important consideration when examining heterogeneous cellular staining. We expect that this method will be useful for assessment of heterogeneous staining with any antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354

    Article  CAS  PubMed  Google Scholar 

  2. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  CAS  PubMed  Google Scholar 

  3. Liu L, Gerson SL (2006) Targeted modulation of MGMT: clinical implications. Clin Cancer Res 12:328–331

    Article  CAS  PubMed  Google Scholar 

  4. Brell M, Tortosa A, Verger E et al (2005) Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11:5167–5174

    Article  CAS  PubMed  Google Scholar 

  5. Cankovic M, Mikkelsen T, Rosenblum ML et al (2007) A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 87:392–397

    CAS  PubMed  Google Scholar 

  6. Cao VT, Jung TY, Jung S et al (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 65:866–875

    Article  PubMed  Google Scholar 

  7. Karayan-Tapon L, Quillien V, Guilhot J et al (2010) Prognostic value of O(6)-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97:311–322

    Article  CAS  PubMed  Google Scholar 

  8. Parkinson JF, Wheeler HR, Clarkson A et al (2008) Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 87:71–78

    Article  CAS  PubMed  Google Scholar 

  9. Sonoda Y, Yokosawa M, Saito R et al (2010) O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 15:352–358

    Article  CAS  PubMed  Google Scholar 

  10. Maxwell JA, Johnson SP, Quinn JA et al (2006) Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 5:2531–2539

    Article  CAS  PubMed  Google Scholar 

  11. Metellus P, Coulibaly B, Nanni I et al (2009) Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 115:4783–4794

    Article  CAS  PubMed  Google Scholar 

  12. Sasai K, Nodashira M, Nishihara H et al (2008) Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 32:1220–1227

    Article  PubMed  Google Scholar 

  13. Preusser M, Janzer RC, Felsberg J et al (2008) Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520–532

    CAS  PubMed  Google Scholar 

  14. Anda T, Shabani HK, Tsunoda K et al (2003) Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res 25:241–248

    Article  CAS  PubMed  Google Scholar 

  15. Preusser M (2009) MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol Histopathol 24:511–518

    CAS  PubMed  Google Scholar 

  16. Felsberg J, Rapp M, Loeser S et al (2009) Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 15:6683–6693

    Article  CAS  PubMed  Google Scholar 

  17. Grasbon-Frodl EM, Kreth FW, Ruiter M et al (2007) Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 121:2458–2464

    Article  CAS  PubMed  Google Scholar 

  18. Mollemann M, Wolter M, Felsberg J et al (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379–385

    Article  PubMed  Google Scholar 

  19. Nakagawa T, Ido K, Sakuma T et al (2009) Prognostic significance of the immunohistochemical expression of O(6)-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology 29:379–388

    Article  PubMed  Google Scholar 

  20. Nakasu S, Fukami T, Baba K et al (2004) Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 70:333–340

    Article  PubMed  Google Scholar 

  21. Sonoda Y, Kumabe T, Watanabe M et al (2009) Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien) 151:1349–1358

    Article  Google Scholar 

  22. Yachi K, Watanabe T, Ohta T et al (2008) Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. Int J Oncol 33:469–475

    CAS  PubMed  Google Scholar 

  23. Cloughesy TF, Yoshimoto K, Nghiemphu P et al (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8

    Article  PubMed  Google Scholar 

  24. Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024

    Article  CAS  PubMed  Google Scholar 

  25. Kleihues P, Burger PC, Aldape KD, Brat DJ et al (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD et al (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC, Lyon, pp 33–49

    Google Scholar 

  26. Eoli M, Pollo B, Bianchessi F et al (2006) Molecular markers of gliomas: a clinical approach. Neurol Res 28:538–541

    Article  CAS  PubMed  Google Scholar 

  27. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466

    Article  CAS  PubMed  Google Scholar 

  28. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003

    Article  CAS  PubMed  Google Scholar 

  29. Stupp R, Hegi ME, Mark R et al (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127–4136

    Article  CAS  PubMed  Google Scholar 

  30. Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388–2399

    Article  CAS  PubMed  Google Scholar 

  31. Srivenugopal KS, Yuan XH, Friedman HS et al (1996) Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry 35:1328–1334

    Article  CAS  PubMed  Google Scholar 

  32. Zaidi NH, Liu L, Gerson SL (1996) Quantitative immunohistochemical estimates of O6-alkylguanine-DNA alkyltransferase expression in normal and malignant human colon. Clin Cancer Res 2:577–584

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

    Yukie Araki, Masahiro Mizoguchi, Koji Yoshimoto, Tadahisa Shono, Toshiyuki Amano, Akira Nakamizo & Tomio Sasaki

  2. Department of Neuropathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Satoshi O. Suzuki & Toru Iwaki

Authors
  1. Yukie Araki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiro Mizoguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Yoshimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tadahisa Shono
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toshiyuki Amano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akira Nakamizo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Satoshi O. Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toru Iwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomio Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yukie Araki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Araki, Y., Mizoguchi, M., Yoshimoto, K. et al. Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue. Brain Tumor Pathol 28, 25–31 (2011). https://doi.org/10.1007/s10014-010-0004-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10014-010-0004-2

Keywords

Search

Navigation